PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...

Autoimmune and inflammatory disease prevention and interception play Provention Bio Inc. (Lebanon, N.J.) said it raised $28.4 million in a series A round from the Johnson & Johnson Innovation-JJDC Inc. arm of Johnson & Johnson...

Newco Celimmune launched to acquire, develop and commercialize therapeutics to treat and prevent immune disorders. The company will initially focus on diet non-responsive celiac disease and refractory celiac disease, which is a T cell lymphoma...